Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies

被引：0
作者：
Granica, Monika [1 ,2 ,3 ]
Laskowski, Gustaw [2 ]
Link-Lenczowski, Pawel [4 ,5 ]
Graczyk-Jarzynka, Agnieszka [2 ]
机构：
[1] Med Univ Warsaw, Dept Immunol, PL-02097 Warsaw, Poland
[2] Polish Acad Sci, Dept Immunol, Mossakowski Med Res Inst, PL-02106 Warsaw, Poland
[3] Med Univ Warsaw, Doctoral Sch, PL-02091 Warsaw, Poland
[4] Jagiellonian Univ Med Coll, Fac Hlth Sci, Dept Med Physiol, PL-31126 Krakow, Poland
[5] Jagiellonian Univ Med Coll, Ctr Dev Therapies Civilizat & Age Related Dis, PL-31066 Krakow, Poland
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2025年 / 1880卷 / 02期
关键词：
Immunotherapy; PD-L1; PD-1; PD-L2; N-glycosylation; Checkpoints; CELL CARCINOMA; B7; FAMILY; EXPRESSION; MEMBER; MICROENVIRONMENT; BLOCKADE; RECEPTOR; PATHWAY; EVASION;
D O I：
10.1016/j.bbcan.2025.189274
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The modulation of the N-glycosylation status in immune checkpoints, particularly the PD-1/PD-L1 axis, has emerged as a promising approach to enhance cancer immunotherapies. While immune checkpoint inhibitors (ICIs) targeting PD-1 and PD-L1 have achieved significant clinical success, recent studies highlight the critical role ofNglycosylation in regulating their expression, stability, and function. Alterations in N-glycosylation might affect the efficacy of ICIs by modulating the interactions between immune checkpoints and antibodies used in therapy. This review focuses on the glycosylation of PD-1 and its ligands PD-L1 and PD-L2, examining how Nglycans influence immune responses and contribute to immune evasion by tumors. It explores innovative strategies to modulate glycosylation in tumor and immune cells, including the use ofNglycosylation inhibitors and novel genetic manipulation techniques. Understanding the interplay betweenNglycosylation and immune checkpoint functions is essential for optimizing immunotherapy outcomes and overcoming therapeutic resistance in cancer patients.
引用
收藏
页数：9
相关论文
共 83 条
[21]  
Sun L., Li C.W., Chung E.M., Yang R., Kim Y.S., Park A.H., Lai Y.J., Yang Y., Wang Y.H., Liu J., Qiu Y., Khoo K.H., Yao J., Hsu J.L., Cha J.H., Chan L.C., Hsu J.M., Lee H.H., Yoo S.S., Hung M.C., Targeting glycosylated PD-1 induces potent antitumor immunity, Cancer Res., 80, pp. 2298-2310, (2020)
[22]  
Wu Z., Cao Z., Yao H., Yan X., Xu W., Zhang M., Jiao Z., Zhang Z., Chen J., Liu Y., Zhang M., Wang D., Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2, Cell Rep., 42, (2023)
[23]  
Han Y., Liu D., Li L., PD-1/PD-L1 pathway: current researches in cancer, Am. J. Cancer Res., 10, pp. 727-742, (2020)
[24]  
Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., Sharpe A.H., Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses, Eur. J. Immunol., 33, pp. 2706-2716, (2003)
[25]  
Sunshine J.C., Nguyen P.L., Kaunitz G.J., Cottrell T.R., Berry S., Esandrio J., Xu H., Ogurtsova A., Bleich K.B., Cornish T.C., Lipson E.J., Anders R.A., Taube J.M., PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison, Clin. Cancer Res., 23, pp. 4938-4944, (2017)
[26]  
Yu W., Hua Y., Qiu H., Hao J., Zou K., Li Z., Hu S., Guo P., Chen M., Sui S., Xiong Y., Li F., Lu J., Guo W., Luo G., Deng W., PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer, Cell Death Dis., 11, (2020)
[27]  
Li C., Lim S., Chung E.M., Kim Y., Park A.H., Yao J., Cha J., Xia W., Chan L., Kim T., Chang S., Lee H., Chou C., Liu Y., Yeh H., Perillo E.P., Dunn A.K., Kuo C., Khoo K., Hsu J.L., Wu Y., Yamaguchi H., Huang T., Sahin A.A., Hortobagyi G.N., Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1, Cancer Cell, 33, pp. 187-201, (2018)
[28]  
Leite K.R.M., Morais D.R., Massoco C., Reis S.T., Viana N.I., Silva I.A., Guimaraes V., Pimenta R., Arantes G., Srougi M., Nahas W.C., BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells, Surg. Exp. Pathol., 5, (2022)
[29]  
Nomi T., Sho M., Akahori T., Hamada K., Kubo A., Kanehiro H., Nakamura S., Enomoto K., Yagita H., Azuma M., Nakajima Y., Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer, Clin. Cancer Res., 13, pp. 2151-2157, (2007)
[30]  
Alwosaibai K., Aalmri S., Mashhour M., Ghandorah S., Alshangiti A., Azam F., Selwi W., Gharaibeh L., Alatawi Y., Alruwaii Z., Alsaab H.O., PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers, BMC Cancer, 23, pp. 1-16, (2023)
123456789